RE: accustem12 Feb 2021 06:29
1 New Accustem Sciences (Accustem) share for each Existing Tiziana Life Sciences (Tiziana) share held on the Ex-entitlement Date, 30th October 2020.
On 16th September 2020, Tiziana announced that following a strategic review of its clinical trial programs and core focus, the Company intends to demerge its StemPrintER and SPARE genomics-based personalised medicine business, Accustem, into a separate and independent listed Company.
The Demerger is subject to shareholder approval at the General Meeting to be held on 2nd October 2020.
Subsequently, the Demerger is expected to become effective on 30th October 2020. However, it is not yet known when the New Accustem shares will be received.